Logo

American Heart Association

  15
  0


Final ID: MP2343

Artificial Intelligence-Derived Myosteatosis on Coronary Artery Calcium CT Scans Predicts Incident COPD: An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

Abstract Body (Do not enter title and authors here): Introduction/Background
Myosteatosis, defined as pathological fat infiltration into skeletal muscle, is an emerging marker of metabolic dysfunction and cardiovascular risk, particularly when measured in abdominal CT. However, its association with lung health and risk of chronic obstructive pulmonary disease (COPD) is not well established. The AI-CVD initiative aims to extract all useful opportunistic screening information from coronary artery calcium scans and combines them with traditional risk factors to create a stronger predictor of cardiovascular diseases. We hypothesized that myosteatosis measured from cardiac CT scans using AI-CVD is associated with increased risk of incident COPD in a population free of clinical cardiovascular disease at baseline.

Methods/Approach
A retrospective cohort analysis was conducted using baseline data from Exam 1 of the Multi-Ethnic Study of Atherosclerosis including men and women aged 45 to 84 free of cardiovascular disease at baseline. Myosteatosis was quantified using AI-CVD to segment muscle and compute thoracic skeletal muscle density as a proxy for fat infiltration. Chronic obstructive pulmonary disease (COPD) was defined using clinical diagnosis with ICD codes. Proportional hazards models were used to assess the association between myosteatosis and incident COPD disease over 15 years. Models were adjusted for confounders including age, sex, pack years of smoking, emphysema, body mass index, inflammation, diabetes, and socioeconomic status.
Results/Data
A total of 283 cases of incident COPD were identified. Individuals in the lowest quartile of muscle attenuation had significantly higher cumulative incidence compared to other quartiles. In minimally adjusted models, the hazard ratio comparing the lowest to highest quartile was 1.87. In fully adjusted models, the association remained significant with a hazard ratio of 1.32.
Conclusion(s)
AI-based quantification of myosteatosis on routine cardiac CT scans independently predicts future risk of COPD. Adverse muscle composition in the pectoralis, intercostal, and paraspinal muscles may precede lung function decline. Opportunistic assessment of myosteatosis could enable early identification of individuals at elevated risk and support preventive interventions at elevated risk for COPD and guide preventive strategies before clinical disease onset.
  • Naghavi, Morteza  ( HeartLung Technologies , Houston , Texas , United States )
  • Maron, David  ( STANFORD UNIVERSITY , Palo Alto , California , United States )
  • Vliegenthart, Rozemarijn  ( University Medical Center Groningen , Groningen , Netherlands )
  • Mcconnell, Michael  ( Stanford University , Palo Alto , California , United States )
  • Zulueta, Javier  ( Mount Sinai Hospital , New York , New York , United States )
  • Williams, Kim  ( University of Louisville Medicine , Louisville , Kentucky , United States )
  • Branch, Andrea  ( Mount Sinai Hospital , New York , New York , United States )
  • Mechanick, Jeffrey  ( icahn school of med at mount siani , New York , New York , United States )
  • Ma, Ning  ( Mount Sinai Hospital , New York , New York , United States )
  • Yip, Rowena  ( Icahn School of Med at Mt Sinai , New York , New York , United States )
  • Fan, Wenjun  ( University of California Irvine , Irvine , California , United States )
  • Azimi, Amir  ( HeartLung Technologies , Houston , Texas , United States )
  • Roy, Sion  ( UCLA Harbor , Malibu , California , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Molloi, Sabee  ( University of California, Irvine , Irvine , California , United States )
  • Kakadiaris, Ioannis  ( University of Houston , Houston , Texas , United States )
  • Shah, Prediman  ( Cedars-Sinai Medical Center , Los Angeles , California , United States )
  • Abela, George  ( MICHIGAN STATE UNIV , East Lansing , Michigan , United States )
  • Narula, Jagat  ( UTHealth Houston , Houston , Texas , United States )
  • Benjamin, Emelia  ( Boston University School Medicine , Brookline , Massachusetts , United States )
  • Levy, Daniel  ( NHLBI-FRAMINGHAM HEART STUDY , Newton Highlands , Massachusetts , United States )
  • Mehran, Roxana  ( Icahn School of Med. at Mount Sinai , New York , New York , United States )
  • Atlas, Kyle  ( HeartLung Technologies , Houston , Texas , United States )
  • Kloner, Robert  ( Huntington Medical Research Inst. , Pasadena , California , United States )
  • Zhang, Chenyu  ( HeartLung Technologies , Houston , Texas , United States )
  • Reeves, Anthony  ( Cornell University , Ithaca , New York , United States )
  • Wasserthal, Jakob  ( University Basel , Basel , Switzerland )
  • Wong, Nathan  ( University of California, Irvine , Irvine , California , United States )
  • Henschke, Claudia  ( Mount Sinai Hospital , New York , New York , United States )
  • Yankelevitz, David  ( Mount Sinai Hospital , New York , New York , United States )
  • Author Disclosures:
    Morteza Naghavi: DO have relevant financial relationships ; Ownership Interest:HeartLung.AI:Active (exists now) | David Maron: DO have relevant financial relationships ; Advisor:New Amsterdam:Past (completed) ; Individual Stocks/Stock Options:Ablative Solutions:Active (exists now) ; Consultant:Inno Med:Past (completed) ; Consultant:Scilex:Past (completed) ; Independent Contractor:J&J:Active (exists now) ; Consultant:Regeneron:Past (completed) ; Consultant:Hearlflow:Active (exists now) ; Research Funding (PI or named investigator):Omada Health:Active (exists now) ; Research Funding (PI or named investigator):Cleerly:Active (exists now) | Rozemarijn Vliegenthart: DO have relevant financial relationships ; Research Funding (PI or named investigator):Siemens Healthineers:Active (exists now) ; Speaker:Wiley:Past (completed) ; Speaker:Bayer Healthcare:Active (exists now) ; Speaker:Siemens Healthineers:Active (exists now) | Michael McConnell: DO have relevant financial relationships ; Employee:Toku:Active (exists now) ; Advisor:Galenband:Active (exists now) ; Advisor:Porter Health:Active (exists now) | Javier Zulueta: No Answer | Kim Williams: DO NOT have relevant financial relationships | Andrea Branch: DO NOT have relevant financial relationships | Jeffrey mechanick: DO have relevant financial relationships ; Advisor:Abbott Nutrition:Active (exists now) ; Speaker:Merck:Active (exists now) ; Speaker:Abbott Nutrition:Active (exists now) ; Advisor:Twin Health:Active (exists now) | Ning Ma: No Answer | Rowena Yip: No Answer | WENJUN FAN: DO NOT have relevant financial relationships | Amir Azimi: No Answer | Sion Roy: DO NOT have relevant financial relationships | Matthew Budoff: DO have relevant financial relationships ; Researcher:Lilly:Active (exists now) ; Speaker:Boehringer-Ingleheim:Active (exists now) ; Speaker:Lilly:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now) | Sabee Molloi: DO NOT have relevant financial relationships | Ioannis Kakadiaris: No Answer | Prediman Shah: No Answer | George Abela: DO NOT have relevant financial relationships | Jagat Narula: DO NOT have relevant financial relationships | Emelia Benjamin: DO NOT have relevant financial relationships | Daniel Levy: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Elsevier Publishing:Active (exists now) | Roxana Mehran: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, CPC Clinical Research, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess Fund Management, Sanofi US Services, Inc.:Active (exists now) ; Other (please indicate in the box next to the company name):Honorarium: AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program):Active (exists now) ; Other (please indicate in the box next to the company name):No Fees from: SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director):Active (exists now) ; Individual Stocks/Stock Options:Elixir Medical, Stel, ControlRad (spouse):Active (exists now) ; Advisor:Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk:Active (exists now) | Kyle Atlas: No Answer | Robert Kloner: DO have relevant financial relationships ; Consultant:Hoskinson Health Clinic:Active (exists now) | Chenyu Zhang: DO have relevant financial relationships ; Employee:HeartLung Corporation:Active (exists now) ; Individual Stocks/Stock Options:HeartLung Corporation:Active (exists now) | Anthony Reeves: DO have relevant financial relationships ; Individual Stocks/Stock Options:HeartLung Technologies:Active (exists now) | Jakob Wasserthal: DO have relevant financial relationships ; Consultant:HeartLungAi:Active (exists now) | Nathan Wong: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen, Novartis, Ionis:Active (exists now) ; Consultant:Ionis:Past (completed) ; Speaker:Novartis:Past (completed) ; Consultant:Heart Lung, Amgen, Novartis:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk, Regeneron:Past (completed) | Claudia Henschke: No Answer | David Yankelevitz: DO have relevant financial relationships ; Royalties/Patent Beneficiary:General Electric:Active (exists now) ; Individual Stocks/Stock Options:Accumetra:Active (exists now) ; Advisor:Lunglife AI:Active (exists now) ; Advisor:Carestream:Active (exists now) ; Advisor:Median Technology:Active (exists now) ; Individual Stocks/Stock Options:HeartLung:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:
More abstracts on this topic:
Age and White Matter Injury due to Cerebral Small Vessel Disease are Synergistically Associated with Impaired Neurovascular Coupling.

Yang Sheng, Webb Alastair

2-Deoxyuridine Associates with Recurrent Coronary Events

Pistritu Dan, Castano David, Liehn Elisa, Koh Cho Yeow, Gerszten Robert, Singaraja Roshni, Chan Mark, Shah Svati

More abstracts from these authors:
AI-driven Measurement of Myosteatosis in Coronary Artery Calcium Scans Predicts Atrial Fibrillation and Heart Failure. An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis (MESA)

Naghavi Morteza, Wong Nathan, Vliegenthart Rozemarijn, Mcconnell Michael, Maron David, Branch Andrea, Kloner Robert, Mechanick Jeffrey, Ma Ning, Yip Rowena, Fan Wenjun, Azimi Amir, Roy Sion, Nasir Khurram, Molloi Sabee, Fayad Zahi, Kakadiaris Ioannis, Abela George, Narula Jagat, Williams Kim, Shah Prediman, Benjamin Emelia, Atlas Kyle, Levy Daniel, Zhang Chenyu, Reeves Anthony, Atlas Thomas, Yankelevitz David, Mirjalili Seyed Reza, Henschke Claudia

AI-CVD: Artificial Intelligence-Enabled Opportunistic Screening of Coronary Artery Calcium Computed Tomography Scans for Predicting CVD Events and All-Cause Mortality: The Multi-Ethnic Study of Atherosclerosis (MESA)

Naghavi Morteza, Yu Ruilin, Branch Andrea, Ma Ning, Roy Sion, Nasir Khurram, Molloi Sabee, Fayad Zahi, Mcconnell Michael, Kakadiaris Ioannis, Zulueta Javier, Reeves Anthony, Maron David, Shah Prediman, Williams Kim, Abela George, Levy Daniel, Wong Nathan, Atlas Kyle, Zhang Chenyu, Atlas Thomas, Henschke Claudia, Yankelevitz David, Budoff Matthew, Fan Wenjun

You have to be authorized to contact abstract author. Please, Login
Not Available